Data presented at ACG Annual Scientific Meeting

RNS Number : 7582D

Shield Therapeutics PLC

24 October 2022

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

Shield Presents Data at ACG Annual Scientific Meeting 2022 on Accrufer®

London, UK, 24 October 2022: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), announces that a pooled analysis from ferric maltol clinical trials will be presented at the American College of Gastroenterology Annual Scientific Meeting (ACG 2022). ACG 2022 is underway, virtually and in-person, and runs through to 26 October 2022 in Charlotte, North Carolina, USA.

The abstract is available online in the ACG 2022 Abstract Guide: https://acgmeetings.gi.org/

Shield Therapeutics Poster Presentation Details:

Poster:	D0361
Title:	"A pooled analysis of early and sustained response in patients with Inflammatory Bowel Disease (IBD) with Iron Deficiency Anemia (IDA) who were treated with ferric maltol"
Date:	25 October 2022
Time:	10:00AM - 12:00PM ET

ACG 2022 is one of the most prestigious gastrointestinal (GI) clinical conferences, bringing together GI physicians and providing them with the opportunity to network with peers, share experiences from their practice, learn the latest clinical information on key GI topics, and see the latest advances in GI technology and therapeutics throughout the conference.

For further information please contact:

Shield Therapeutics plc	www.shieldtherapeutics.com
Greg Madison, CEO	+44 (0) 191 511 8500
Hans-Peter Rudolf, CFO
Nominated Adviser and Joint Broker
Peel Hunt LLP
James Steel/Christopher Golden	+44 (0)20 7418 8900
Joint Broker finnCap Ltd Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks	+44 (0)20 7220 0500

Financial PR & IR Advisor
Walbrook PR
Lianne Applegarth/Alice Woodings	+44 (0)20 7933 8780 or [email protected]

Investor Contact (US Advisor) LifeSci Advisors, LLC John Mullaly	+1 617 429 3548 or [email protected]

About Accrufer®/Feraccru®

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of action compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s

Accrufer®/Feraccru® are registered trademarks of the Shield Group

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABDBDGCUDDGDB